Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Feature|Articles|March 2, 2024
- Pharmaceutical Technology, March 2024
- Volume 48
- Issue 3
- Pages: 10
Bioprocess Controller
Author(s)Pharmaceutical Technology Editors
Distek has released the BIOne 250 Bioprocess Controller, designed for microbial applications.
Distek has released the BIOne 250 Bioprocess Controller, designed for microbial applications. It is a process-optimized version of the BIOne 1250 benchtop bioreactor system, offering an approachable solution to meet the nuanced requirements of advanced microbial bioprocessing. The controller retains the user interface of the BIOne 1250 via a remote personal computer or monitor, supporting the management of multiple bioreactors from a single central screen.
A standout feature of the BIOne 250 is its scalability, which accommodates the evolving needs of bioprocess applications, making it suitable for scale-down modeling, material generation, and process optimization. The controller is designed for reliability and precision, ensuring consistent and accurate results throughout experiments. The budget-friendly price for the BIOne 250 is intended to make advanced bioprocess control more accessible without sacrificing functionality and quality.
Articles in this issue
over 2 years ago
Reshaping Dosage Formsover 2 years ago
Development of Gamma-Delta T-Cell Therapiesover 2 years ago
Automating the Future of Fill/Finishover 2 years ago
Frontrunners in Bispecific Antibodiesover 2 years ago
Updating Swiss Regulatory Processes in 2024over 2 years ago
Budget Benefitover 2 years ago
First in Line on Catalent’s LineRelated to this article
Sanjay Konagurthu, PhD, senior director of Science and Innovation at Thermo Fisher Scientific, explains what teams need to do to ensure the usefulness of AI and what strides have been made with AI in regulatory submissions.
Pauric Bannigan, Intrepid Labs, explains where AI speeds formulation decisions, why data is the bottleneck, and how active learning trains models with far less data.
The new initiative aims to apply traceable AI and science to expand care worldwide by translating discovery into tools that accelerate drug development.
Sanjay Konagurthu, PhD, senior director, Science and Innovation at Thermo Fisher Scientific, provides an update on the progress of AI and machine learning used in drug delivery.
Stephanie Johnson, Pfizer, explains how off-platform triggers, single-owner risk registers, and traceable prior knowledge keep protein formulation programs on track.
Stephanie Johnson, Pfizer, discusses how platform formulations moved 2 Pfizer protein programs to IND in 8 months by redistributing, not removing risk.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
Trending on Pharmaceutical Technology
1
Pharma Leaders Weigh in On AI's Measurable Results In 2026
2
Humanitas Global Health Launces at AAPS PharmSci 360 Event
3
Manufacturing Intelligence: How AI Poisoning Hides in Plain Sight
4
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
5